Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies.

ABSTRACT: Age-related macular degeneration (AMD), diabetic retinopathy and retinal vein occlusion represent some of the commonest degenerative conditions that lead to severe vision impairment in the developed countries. The gold standard treatment of complications associated with these conditions is the intravitreal administration of anti-vascular endothelial growth factor (VEGF) agents. Brolucizumab is a newly developed, humanised, single-chain fragment of a monoclonal antibody binding all VEGF-A isoforms, which was recently approved for the treatment of neovascular AMD. Intravitreal brolucizumab promises to reduce treatment burden for nAMD patients by achieving comparable therapeutic outcomes with fewer clinic visits. Promising also appears its use for the treatment of more challenging maculopathi

SUBMITTER: Karasavvidou EM 

PROVIDER: S-EPMC9375562 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature